Application of sesquiterpenoid fraction of Yemazhui in preparing medicine for preventing or treating ulcerative colitis

Abstract

The present invention discloses the application of the sesquiterpene part of wild horsetail in the preparation of a drug for preventing or treating ulcerative colitis. The present invention uses sodium dextran sulfate to induce mice to establish an ulcerative colitis mouse model, and the sesquiterpene part of wild horsetail extracted from wild horsetail is used as a therapeutic drug for treating ulcerative colitis, and then the effect of the sesquiterpene part of wild horsetail on the pharmacological indicators of ulcerative colitis mice is observed. The experimental results show that the sesquiterpene part of wild horsetail can reduce the levels of MPO, C3c, TNF‑α, and IL‑6 in the serum of ulcerative colitis mice, increase the level of IL‑10, improve the level of inflammation in ulcerative colitis mice, inhibit the level of complement, improve colon tissue damage, significantly reduce the DAI score, reduce the degree of shortening of the colon, reduce the symptoms of congestion and swelling of the colon, reduce the spleen index, and show a significant anti-ulcerative colitis effect, which can be used to prepare drugs for the prevention and treatment of ulcerative colitis.

Description

Technical Field

[0001] The invention relates to the technical field of biomedicine, and in particular to application of a sesquiterpene fraction of ophiopogon japonicus in preparing a drug for preventing or treating ulcerative colitis. Background Art

[0002] Ulcerative colitis (UC) is a nonspecific inflammatory disease of unknown cause. The lesions are located in the large intestine and are distributed continuously and diffusely, mostly involving the rectum and sigmoid colon. Its typical clinical course includes bloody stools with mucus, pus, abdominal pain, and diarrhea. The disease lasts for a long time and is prone to recurrence and even canceration, which seriously affects the patient's quality of life. At present, the true cause of UC is still unclear. Multiple factors such as immune regulation dysfunction, genetic factors, smoking, diet, living environment, infection, and mental and psychological factors may promote the occurrence and development of this disease. Clinically, the treatment of UC is mainly based on drugs. ① Aminosalicylic acid preparations, such as sulfasalazine, have a long medication cycle and are prone to dose-related adverse reactions, such as gastrointestinal symptoms, urticaria, dyspnea, joint pain, and hepatotoxicity; ② Glucocorticoids and immunosuppressants have many adverse reactions and cannot control UC recurrence; ③ Anti-tumor necrosis factor α monoclonal antibodies are prone to recurrence and have many adverse reactions; ④ Probiotic therapy has a general effect on improving UC symptoms and is often used in combination with other drugs in clinical practice; ⑤ Enema treatments such as tin powder, gentamicin, 2% procaine, and dexamethasone have poor patient compliance (Li Nan, Research Progress in Ulcerative Colitis, Jilin Medicine, 2014, 35(7):1486-1487.; Ma Qinglin, Du Lidong, Zang Kaihong, Sun Min, Cao Rubing, Ren Yuan, Overview of Research Progress in Ulcerative Colitis, Journal of Medical Forum, 2020, 41(1):175-177. Taku Kobayashi, Britta Siegmund, Catherine Le Berre, Shu Chen Wei, Marc Ferrante, Bo Shen, Charles N. Bernstein, Silvio Danese, Laurent Peyrin-Biroulet & Toshifumi Hibi. Ulcerative colitis. Nature Reviews Disease Primers. 2020, 6: 74.).

[0003] The sesquiterpenes fraction of Eupatorium lindleyanum DC refers to the sesquiterpenes fraction of Eupatorium lindleyanum containing sesquiterpenes F, sesquiterpenes G, sesquiterpenes H, sesquiterpenes I and sesquiterpenes K, which has anti-acute lung injury and anti-hepatitis B virus activity (Chunjun Chu, Huiling Ren, Naiyu Xu, LongXia, Daofeng Chen, Jian Zhang. Eupatorium lindleyanum DC. sesquiterpenes fraction attenuates lipopolysaccharide-induced acute lung injury in mice. Journal of Ethnopharmacology.2016,185:263-271.; Zhang Jian, Chu Chunjun, Ren Huiling, Chen Daofeng, Yan Biao, Li Xianlun, Wu Tianwei, Xu Naiyu, Application of sesquiterpenoid fraction of wild horsetail in the preparation of drugs for treating acute lung injury, ZL201410239824.4; Zhang Jian, Chen Daofeng, Ren Huiling, Chu Chunjun, Li Xianlun, Yan Biao, Wu Shuangqing, Application of sesquiterpenoid fraction of wild horsetail in the preparation of drugs for treating hepatitis B virus, ZL201810045554.1; Jiang Xiaogang, Zhang Jian, Zhu Mei, Chen Xihua, Sun Xionghua, Application of sesquiterpenoid lactones of wild horsetail in the preparation of drugs for preventing or treating pulmonary fibrosis, ZL 202210081704.0).

[0004] At present, there is no report on whether the sesquiterpene part of Yemazhui has an anti-ulcerative colitis effect. The present invention finds that the sesquiterpene part of Yemazhui has an anti-ulcerative colitis effect, so the sesquiterpene part of Yemazhui can be used to prepare drugs related to the prevention and treatment of ulcerative colitis. Summary of the invention

[0005] The technical problem to be solved by the present invention is to provide application of the sesquiterpene fraction of Yemazhui in preparing medicine for preventing or treating ulcerative colitis.

[0006] In order to solve the above technical problems, the present invention provides the following technical solutions:

[0007] The first aspect of the present invention provides the use of the sesquiterpene fraction of Yerba zedoaria in preparing a drug for preventing or treating ulcerative colitis.

[0008] Furthermore, the sesquiterpene part of the herba schizophylla preferably comprises the herba schizophylla sesquiterpene part of herba schizophylla lactone F, herba schizophylla lactone G, herba schizophylla lactone H, herba schizophylla lactone I and herba schizophylla lactone K.

[0009] Furthermore, the preparation of the sesquiterpene fraction of the wild horsetail comprises the following steps:

[0010] (1) taking the dried whole herb of Psoralea corylifolia, cutting it into 2-3 cm segments, adding 8-15 times the volume of 60%-95% ethanol aqueous solution, refluxing for 1-3 hours, and recovering the solvent under reduced pressure at 40-60° C. to obtain the Psoralea corylifolia ethanol extract;

[0011] (2) dissolving the ethanol extract of the wild horsetail prepared in step (1) in water to prepare a 0.1-0.2 g / mL solution, adsorbing it on a weakly polar macroporous adsorption resin, first eluting it with water to remove macromolecular compounds, then eluting it with a volume fraction of 90%-95% ethanol aqueous solution, and recovering the solvent under reduced pressure at 40-60° C. to obtain a macroporous resin fraction;

[0012] (3) adsorbing the macroporous resin fraction prepared in step (2) through an ODS reverse phase silica gel column, eluting with a 50% by volume methanol aqueous solution, and recovering the solvent under reduced pressure at 40-60° C. to obtain the sesquiterpene fraction of the wild horsetail.

[0013] Furthermore, in step (2), the weakly polar macroporous adsorption resin is preferably AB-8, D101, HPD-100, HPD-200A, HPD-200B, HPD-300, HPD-700 or HPD-722 macroporous adsorption resin.

[0014] Furthermore, in step (2), in the step of removing the macromolecular compounds by eluting with water, the volume ratio of water to the weakly polar macroporous adsorption resin is 8-15:1, for example 8:1, 9:1, 10:1, 12:1, 13:1, 14:1, 15:1, etc., including but not limited to the volume ratios listed above.

[0015] Furthermore, in step (2), in the step of eluting with a 90%-95% ethanol aqueous solution by volume, the volume ratio of the 90%-95% ethanol aqueous solution to the weakly polar macroporous adsorption resin is 8-15:1, for example, 8:1, 9:1, 10:1, 12:1, 13:1, 14:1, 15:1, etc., including but not limited to the volume ratios listed above.

[0016] Furthermore, in step (3), the ODS reverse-phase silica gel chromatographic column is a DAISOGEL ODS reverse-phase silica gel chromatographic column, a Cosmsil ODS reverse-phase silica gel chromatographic column or a YM CODS-A reverse-phase silica gel chromatographic column; the filler particle size of the ODS reverse-phase silica gel chromatographic column is 50-70 μm, for example, 50 μm, 55 μm, 60 μm, 65 μm, 70 μm, etc., including but not limited to the particle sizes listed above.

[0017] Furthermore, in step (3), in the step of eluting with a 50% methanol aqueous solution by volume, the volume ratio of the 50% methanol aqueous solution to the ODS reverse phase silica gel chromatography column is preferably 4-6:1.

[0018] Further, in step (3), the sesquiterpene part of the wild horsetail contains 2.0%-5.0% of wild horsetail lactone F, 28.0%-35.0% of wild horsetail lactone G, 5.0-8.0% of wild horsetail lactone H, 2.0%-5.0% of wild horsetail lactone I and 44.0%-50.0% of wild horsetail lactone K. For example, the sesquiterpene part of the wild horsetail lactone contains 3.8% of wild horsetail lactone F, 31.4% of wild horsetail lactone G, 6.6% of wild horsetail lactone H, 3.3% of wild horsetail lactone I and 46.3% of wild horsetail lactone K.

[0019] Furthermore, the drug for preventing or treating ulcerative colitis further comprises a pharmaceutically acceptable carrier and / or excipient.

[0020] Furthermore, the auxiliary material is one or more of an antioxidant, a preservative, a solubilizer, a disintegrant, a lubricant, a colorant, a dispersant, and a surfactant.

[0021] Furthermore, the administration method of the drug for preventing or treating ulcerative colitis is preferably gastrointestinal administration.

[0022] Furthermore, in the treatment of ulcerative colitis, the drug is used to reduce the levels of MPO, C3c, TNF-α, and IL-6 in serum.

[0023] Further, in the treatment of ulcerative colitis, the medicament is used to increase IL-10 levels.

[0024] Further, in the treatment of ulcerative colitis, the drug is used to reduce the degree of colon shortening and spleen index.

[0025] Compared with the prior art, the present invention has the following beneficial effects:

[0026] The present invention applies the sesquiterpene part of the wild horsetail to the drugs related to the prevention and treatment of ulcerative colitis for the first time, and verifies it by constructing a mouse ulcerative colitis model. The results show that the sesquiterpene part of the wild horsetail can improve the level of inflammation in mice with ulcerative colitis and inhibit the complement level; it can effectively improve colon tissue damage, significantly reduce the DAI score, reduce the degree of colon shortening, and alleviate the symptoms of colon congestion and swelling; in addition, it can also relieve splenomegaly and reduce the spleen index. The present invention not only verifies that the sesquiterpene part of the wild horsetail has an anti-ulcerative colitis effect through animal experiments, but also studies the mechanism of action of the sesquiterpene part of the wild horsetail on ulcerative colitis, providing a scientific basis for the use of the sesquiterpene part of the wild horsetail for the prevention and treatment of ulcerative colitis. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1HPLC diagram of the sesquiterpene part of ophiopogon, in which ① is the chromatographic peak corresponding to ophiopogon lactone F, ② is the chromatographic peak corresponding to ophiopogon lactone G, ③ is the chromatographic peak corresponding to ophiopogon lactone H, ④ is the chromatographic peak corresponding to ophiopogon lactone I, and ⑤ is the chromatographic peak corresponding to ophiopogon lactone K;

[0028] Figure 2 The curves of DAI scores of mice in different experimental groups are shown in Table 1. Compared with the blank group, #### P<0.0001; compared with the DSS model group, *P<0.05, ***P<0.001, ****P<0.0001, n=6;

[0029] Figure 3 is the colon length of mice in different experimental groups, among which, compared with the blank group, #### P<0.0001; compared with the DSS model group, *P<0.05, ***P<0.001, ****P<0.0001, n=6;

[0030] Figure 4 is the spleen index of mice in different experimental groups, among which, compared with the blank group, #### P<0.0001; compared with the DSS model group, *P<0.05, ****P<0.0001, n=6;

[0031] Figure 5 is the C3c content in the serum of mice in different experimental groups. Compared with the blank group, #### P<0.0001; compared with the DSS model group, ****P<0.0001, n=6;

[0032] Figure 6 is the content of IL-6, IL-10 and TNF-α in the serum of mice in different experimental groups. Compared with the blank group, #### P<0.0001; compared with the DSS model group, **P<0.01, ***P<0.001, ****P<0.0001, n=6;

[0033] Figure 7 is the MPO content in the serum of mice in different experimental groups. Compared with the blank group, ### P<0.001; compared with the DSS model group, **P<0.01, ***P<0.001, n=6;

[0034] Figure 8 These are the H&E staining images of the colon tissues of mice in different experimental groups, a: blank group, b: model group, c: Yemazhui sesquiterpene part group, d: positive drug group. DETAILED DESCRIPTION

[0035] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art of the present invention. The terms used herein in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The term "and / or" used herein includes any and all combinations of one or more related listed items.

[0036] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.

[0037] Example

[0038] 1. Purpose of the experiment

[0039] To observe the effects of the sesquiterpenoid fractions of YEMAZHUAI on the pharmacological indices of mice with ulcerative colitis, including DAI score, colon length, spleen index, colon tissue damage, serum inflammatory factor levels and complement.

[0040] 2. Experimental Materials

[0041] Experimental medicinal materials and reagents: Yemazhui medicinal materials were purchased from Huai'an Xuyi Defeng Chinese Medicinal Materials Planting Company; dextran sulfate sodium was purchased from Shanghai Xibao Biotechnology Co., Ltd.; toluene, ammonia water, hydrochloric acid, anhydrous ethanol and neutral gum were purchased from Sinopharm Chemical Reagent Co., Ltd.; sulfasalazine enteric-coated tablets were purchased from Shanghai Xinyi Tianping Pharmaceutical Co., Ltd.; ELISA kits for TNF-α, IL-10, IL-6, C3c, and MPO were purchased from Shanghai Meike Biotechnology Co., Ltd.; other chemical reagents were of analytical grade.

[0042] Experimental instruments: 702-80℃ refrigerator, produced by Thermo Fisher Scientific Inc., USA; TECAN full-wavelength microplate reader, model M1000 pro, produced by Nanjing Kelinde Scientific Instrument Co., Ltd.; incubator, produced by Shanghai Jinghong Experimental Equipment Co., Ltd.; balance, produced by Ohaus Instrument Co., Ltd.; water bath, produced by Shanghai Ailan Instrument Co., Ltd.; pathological slicer, produced by Shanghai Leica Instrument Co., Ltd.; tissue spreader, produced by Cody Instrument Equipment Co., Ltd., Jinhua City, Zhejiang Province; oven, produced by Shanghai Huitai Instrument Manufacturing Co., Ltd.; slides and cover slips, produced by Jiangsu Shitai Experimental Equipment Co., Ltd.; inverted optical microscope and imaging system, produced by Nikon, Japan; dehydrator, embedding machine and freezing table, produced by Wuhan Junjie Electronics Co., Ltd.; high performance liquid chromatograph, model Agilent 1260Infinity, produced by Agilent Technologies, USA.

[0043] 3. Experimental Methods

[0044] Preparation of the ethanol extract of Z. truncatum: weigh 100 g of dried whole herb of Z. truncatum, cut it into 2-3 cm segments, add 10 times the volume of 80% ethanol aqueous solution, reflux extraction for 2 hours, repeat 2 times, recover the solvent under reduced pressure at 40°C, and obtain 15 g of Z. truncatum ethanol extract (ZTW).

[0045] Preparation of the sesquiterpene fraction of Herba Cibotii: The ethanol extract of Herba Cibotii was dissolved in about 90 mL of water, adsorbed with 170 mL of D101 macroporous adsorption resin, firstly eluted with 1700 mL of water to remove macromolecular compounds, then eluted with 1700 mL of 95% ethanol aqueous solution by volume, and the solvent was recovered under reduced pressure to obtain 5 g of macroporous resin fraction; the obtained macroporous resin fraction was adsorbed on a 120 mL YMCODS-A reverse-phase silica gel filler with a particle size of 60 μm reverse-phase silica gel chromatography column, eluted with 550 mL of 50% methanol aqueous solution by volume, and the solvent was recovered under reduced pressure at 40°C to obtain 1.8 g of the sesquiterpene fraction (SQT) of Herba Cibotii.

[0046] The components of the sesquiterpenoid part (SQT) of YEMACHUI were determined by high performance liquid chromatography, wherein mobile phase A was acetonitrile; mobile phase B was water; mobile phase conditions: 0 min: 30% A, 5 min: 30% A, 15 min: 32% A, 25 min: 36% A; 40 min: 36% A. Chromatographic column: YMC-PACK ODS-A (Ф4.6 mm×250 mm, 5 μm); column temperature: 28°C; detection wavelength: 210 nm; injection volume: 20 μl; flow rate: 1 mL·min -1 .

[0047] Accurately weigh the reference substances, 6.02 mg of yemachai lactone F, 14.94 mg of yemachai lactone G, 5.08 mg of yemachai lactone H, 10.04 mg of yemachai lactone I, and 13.98 mg of yemachai lactone K, and dilute to 10 mL with mobile phase A as a stock solution. Each group of reference substances was diluted with mobile phase A to 1:2, 1:4, 1:8, 1:16, and 1:32, filtered with a 0.22 μm filter membrane, and the filtrate was set aside. Five concentrations of solutions of each group of reference substances were taken for chromatographic determination, and a standard curve was drawn. Each concentration point was analyzed in parallel 3 times. The peak area of ​​each chromatographic peak was recorded, and the concentration (x) was linearly regressed with the peak area (y) of the reference substance to obtain the standard curve of the reference substance: y=63403x-15.408 for yemachaylactone F; y=24720x-20.065 for yemachaylactone G; y=79063x+6.7811 for yemachaylactone H; y=239018x+53.303 for yemachaylactone I; and y=7913.5x+62.857 for yemachaylactone K.

[0048] Accurately weigh 6 mg of SQT from the sesquiterpene fraction of Yemazhui, and dilute to 10 mL volumetric flask with mobile phase A, filter with a 0.22 μm filter membrane, and reserve the filtrate for later use. Take the filtrate for chromatographic determination. Figure 1 As shown in the figure, through the analysis of the HPLC results, it can be concluded that the sesquiterpenoid fraction (SQT) sample of Yemazhu contains

[0049] 3.8% of phytolactone F, 31.4% of phytolactone G, 6.6% of phytolactone H, 3.3% of phytolactone I and 46.3% of phytolactone K.

[0050] Animal grouping, modeling and drug administration: Male C57BL / 6J mice were divided into blank group (Control), model group (Model), ZTW group, SQT group, and positive drug group (Positive, sulfasalazine) with 6 mice in each group after adaptive culture. Except for the blank group, the model group, ZTW ethanol extract group, SQT group, and positive drug group were all given 2.5% DSS solution for drinking, and the 2.5% DSS solution was changed every 3 days for 7 consecutive days. From the second day, ZTW total extract, SQT group, and positive drug were given intragastric administration. The blank group was given normal saline for 8 consecutive days. The ZTW ethanol extract group and SQT group were both given 0.2 g / kg, and the positive drug group was given 0.25 g / kg.

[0051] Determination of pharmacological indicators: According to the Cooper scoring system (as shown in Table 1 below), the disease activity index (DAI) of the colon tissue of mice was assessed daily based on the weight loss, stool characteristics, and blood in the stool of mice. On the 9th day, half an hour after the last administration, blood was collected from the eyeball of the mice, stored at 4°C, centrifuged at 3500rpm for 6 minutes, and serum was collected and stored at -80°C for MPO, IL-6, IL-10, TNF-α and C3c determination; the colon tissue of mice was collected in paraformaldehyde fixative for H&E staining observation; the spleen was collected for weighing and the spleen index was calculated.

[0052] Table 1 Disease Activity Index (DAI) Scoring Criteria

[0053]

[0054] 4. Experimental Results

[0055] The following experimental data results are expressed as mean ± standard deviation (x ± SD). SPSS 21.0 was used to perform one-way analysis of variance on multiple groups of measurement data, and t-test was used for inter-group comparison. P < 0.05 was considered statistically significant. SPSS 21.0 was used to perform Turkey-HSD rank sum test on OUT.

[0056] DAI score: Figure 2 As shown, on the last day of modeling, the DAI score of mice in the model group was significantly higher than that in the blank group (P<0.0001); 8 days after oral administration, compared with the DSS model group, the DAI score of mice in the Yemazhui sesquiterpene fraction group (SQT in the figure) was significantly lower (P<0.0001), and was better than that in the positive drug group (Positive in the figure).

[0057] Colon length: Figure 3 As shown, compared with the blank group, the colon length of mice in the model group was significantly shortened (P<0.0001); compared with the DSS model group, the degree of shortening of the colon of mice in the sesquiterpene fraction group of Yemazhui (SQT in the figure) was reduced (P<0.05).

[0058] Spleen index: Figure 4 As shown, compared with the blank group, the spleen index of mice in the DSS model group was significantly increased (P<0.0001); compared with the DSS model group, the spleen index of mice in the Echinops ethanol extract group (ZTW in the figure), the Echinops sesquiterpenoid part group (SQT in the figure) and the positive drug group (Positive in the figure) were all decreased, among which the Echinops sesquiterpenoid part group had the most obvious effect in reducing the spleen index of mice (P<0.0001), which was close to the blank group, while the data of the positive drug group (Positive in the figure) were not statistically significant.

[0059] Serum complement C3c level: Figure 5 As shown, compared with the blank group, the complement C3c level in the serum of mice in the DSS model group was significantly increased (P<0.0001); compared with the DSS model group, the complement C3c level in the serum of mice in the Echinops ethanol extract group (ZTW in the figure), the Echinops sesquiterpenoid group (SQT in the figure) and the positive drug group (Positive in the figure) was significantly decreased, among which the complement C3c level in the serum of mice in the Echinops sesquiterpenoid group was similar to that in the blank group (P<0.0001), showing a significant inhibitory effect on the complement level.

[0060] Serum inflammatory factor levels: Figure 6 As shown in the figure, the levels of serum TNF-α and IL-6 in the model group mice were significantly higher than those in the blank group (P<0.0001), while the level of IL-10 was significantly lower than that in the blank group (P<0.0001). Compared with the model group, the levels of serum TNF-α and IL-6 in the Yemazhu sesquiterpene fraction group (SQT in the figure, TNF-α: P<0.0001, IL-6: P<0.01) were significantly lower, while the level of IL-10 was significantly increased (P<0.0001). Figure 7The figure is the myeloperoxidase (MPO) level of mice in different experimental groups. It can be seen from the figure that the MPO level of mice in the model group was significantly higher than that in the blank group (P<0.001). Compared with the model group, the MPO level in the serum of mice in the sesquiterpene fraction group of Yemazhui was significantly decreased (P<0.01).

[0061] H&E staining of colon tissue: Figure 8 As shown in the figure, the colon tissue structure of mice in the blank group was normal, the mucosal epithelial structure was intact, the glandular structure was intact and neatly arranged, and there was no obvious pathological change; the colon mucosal epithelium of mice in the DSS model group was severely damaged and disordered, the glands were deformed or even disappeared, and a large number of inflammatory cells were observed in the mucosa and its lower layer, indicating that the mouse UC model was successfully established. Compared with the DSS model group, the degree of colon mucosal damage in the mice in the sesquiterpene fraction group of Yemazhui was significantly improved, the mucosal glands were neatly arranged, the intestinal wall was basically restored, the muscular layer lesions were significantly alleviated, and the inflammatory infiltration was alleviated.

[0062] 5. Conclusion

[0063] The above experimental results show that the sesquiterpene part group of Mustard can reduce the levels of MPO, C3c, TNF-α, and IL-6 in the serum of mice with ulcerative colitis, increase the level of IL-10, improve the inflammation level in the body of mice with ulcerative colitis, inhibit the complement level, improve colon tissue damage, significantly reduce the DAI score, reduce the degree of colon shortening, and alleviate the symptoms of colon congestion and swelling; relieve splenomegaly and reduce the spleen index.

[0064] The above-described embodiments are only preferred embodiments for fully illustrating the present invention, and the protection scope of the present invention is not limited thereto. Equivalent substitutions or changes made by those skilled in the art based on the present invention are within the protection scope of the present invention. The protection scope of the present invention shall be subject to the claims.

Claims

1. Application of the sesquiterpene fraction of Yemazhui in the preparation of a drug for treating ulcerative colitis, characterized in that: The sesquiterpene part of the wild horsetail refers to the sesquiterpene part of the wild horsetail containing wild horsetail lactone F, wild horsetail lactone G, wild horsetail lactone H, wild horsetail lactone I and wild horsetail lactone K; The preparation of the sesquiterpene fraction of Yemazhui comprises the following steps: (1) Take the dried whole herb of Psoralea corylifolia, cut it into 2-3 cm segments, add 8-15 times the volume of 60%-95% ethanol aqueous solution, reflux extraction for 1-3 hours, and recover the solvent under reduced pressure at 40-60 °C to obtain Psoralea corylifolia ethanol extract; (2) dissolving the ethanol extract of the wild horsetail prepared in step (1) in water to prepare a 0.1-0.2 g / mL solution, adsorbing it on a weakly polar macroporous adsorption resin, first eluting it with water to remove macromolecular compounds, then eluting it with a 90%-95% ethanol aqueous solution by volume, and recovering the solvent under reduced pressure at 40-60° C. to obtain a macroporous resin fraction; (3) The macroporous resin fraction prepared in step (2) is adsorbed on an ODS reverse phase silica gel column, eluted with a 50% by volume methanol aqueous solution, and the solvent is recovered under reduced pressure at 40-60° C. to obtain the sesquiterpene fraction of the wild horsetail.

2. The use according to claim 1, characterized in that: In step (2), the weakly polar macroporous adsorption resin is AB-8, D101, HPD-100, HPD-200A, HPD-200B, HPD-300, HPD-700 or HPD-722 macroporous adsorption resin.

3. The use according to claim 1, characterized in that: In step (3), the ODS reverse-phase silica gel chromatographic column is a DAISOGEL ODS reverse-phase silica gel chromatographic column, a Cosmsil ODS reverse-phase silica gel chromatographic column or a YMC ODS-A reverse-phase silica gel chromatographic column; the filler particle size of the ODS reverse-phase silica gel chromatographic column is 50-70 μm.

4. The use according to claim 1, characterized in that: In step (3), the sesquiterpene fraction of the wild horsetail contains 2.0%-5.0% of wild horsetail lactone F, 28.0%-35.0% of wild horsetail lactone G, 5.0%-8.0% of wild horsetail lactone H, 2.0%-5.0% of wild horsetail lactone I and 44.0%-50.0% of wild horsetail lactone K.

5. The use according to claim 1, characterized in that: The medicine further comprises a pharmaceutically acceptable carrier and / or excipient.

6. The use according to claim 5, characterized in that The auxiliary material is one or more of an antioxidant, a preservative, a solubilizer, a disintegrant, a lubricant, a colorant, a dispersant, and a surfactant.

7. The use according to claim 1, characterized in that: The administration method of the drug for treating ulcerative colitis is gastrointestinal administration.

Images